Now Available:
Download podcasts of MSK video reports

With biweekly and special edition newsletters, Musculoskeletal Report is the top online resource for staying abreast of the most current and clinically relevant information in the field of musculoskeletal disease and treatment.

MSK Report provides cutting-edge scientific updates through in-depth interviews, on-location coverage of medical meetings, expert-led panel discussions, and live newscasts. With an editorial board of internationally recognized thought leaders, MSK Report is positioned to provide unparalleled quality news reporting with the highest level of credibility.

MSK Video Report:


Dr. John Crues presents "Evolution of MRI: A Formidable Radiological Tool for Musculoskeletal Disease" at the International Society of Extremity MRI in Rheumatology (ISEMIR) Conference

Bones: Widely Used Antiepileptic Drug Accelerates Bone Loss in Young Women
Phenytoin, one of the most commonly used antiepileptic drugs (AEDs), causes young women to lose bone mineral density at eight times the normal rate...

Arthritis: Are Rheumatologists Bugging Out Over New RA Treatment?
New research shows that a particular species of Chinese medicinal ant known as Polyrhacis lamellidens, may help fight rheumatoid arthritis and hepatitis...

Bones: Grim Picture Painted for Lupus 5-Year Mortality Risk
Despite some advances in treatment, recently diagnosed lupus patients still face elevated risks of death within 5 years of their diagnosis when compared with lupus-free controls...

Consumer News: Cola May Be Bad to the Bones
High consumption of soda may contribute to lower bone mass and the eventual development of osteoporosis...

BioPharm Business: UCB Launches CIMplicity Program to Provide Comprehensive Treatment Support to Crohn's Disease Patients Receiving Cimzia (certolizumab pegol)
UCB's new CIMplicity program provides Cimzia patients and their caregivers with comprehensive financial, administrative, compliance, and treatment support...

BioPharm Business: Genentech, Biogen Idec Report Phase II/III Trial of Rituxan Fails to Meet Primary or Secondary Endpoints in Lupus
A randomized, double-blind, placebo-controlled, multicenter phase II/III study of Rituxan (rituximab) for systemic lupus erythematosus (SLE) did not meet its primary endpoint or any of the six secondary endpoints...

BioPharm Business: La Jolla Pharmaceutical Reports Positive 12-Month Interim Antibody Data From Phase III Study of Riquent for SLE; Significant, Sustained Reductions Observed in Antibodies to dsDNA
Analyses of data in the first 125 randomized patients indicate that for all patients treated with Riquent compared with placebo, there were significantly greater reductions in antibodies to double-stranded (ds) DNA....

Click here to remove your e-mail address from our mailing list. For questions and comments regarding this newsletter please contact .